Indian Immunologicals says seized Abhayrab vials were not from its authorised supply chain
Indian Immunologicals said Abhayrab rabies-vaccine vials seized in Delhi and deemed substandard were not manufactured by the company. It cited 17 differences versus retained samples and said its Batch KE25012, comprising 83,370 vials, was CDL-certified and distributed only through authorised channels.
What happened
Indian Immunologicals Limited · Indian Immunologicals said seized Abhayrab rabies-vaccine vials deemed substandard were not made by it, citing differences from
Key facts
- Batch KE25012
- 83,370 vials
- 17 differences
Why this matters
The case strengthens the strategic value of partnerships or acquisitions in pharma serialization, authentication and last-mile distribution monitoring.
What to watch
- Drug-controller laboratory findings on the seized vials' composition, sterility, potency and manufacturer attribution.
- Police or regulator identification of supplier invoices, warehouse locations, packaging vendors or arrested distributors.
- Additional seizure notices involving Abhayrab, other rabies vaccines or other products attributed to the same distribution network.
- Any recall, public advisory, distributor suspension or batch-specific verification directive from Indian Immunologicals or regulators.
- Reports of stock-outs, procurement shifts or price increases at hospitals and retail pharmacies in Delhi and neighboring markets.
- Reconcile seized-vial batch markings, packaging features, invoices and chain-of-custody records against Indian Immunologicals' retained samples and authorized-distributor data.
- Require pharmacies, hospitals and wholesalers handling rabies vaccines to quarantine and verify suspect stock before dispensing.
- Expand inspections of Delhi-area wholesale markets, parallel supply routes, storage facilities and online medicine sellers for unauthorized vaccine inventory.
- Accelerate QR, serialization and distributor-to-outlet traceability checks for high-risk, high-urgency biologics.
- Issue clear provider and consumer guidance on verifying authorized supply without disrupting legitimate post-exposure rabies treatment access.